212 related articles for article (PubMed ID: 33341441)
1. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
[TBL] [Abstract][Full Text] [Related]
2. Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model.
Mohan H; Nguyen J; MacKenzie B; Yee A; Laurette EY; Sanghvi T; Tejada O; Dontsova V; Leung KY; Goddard C; De Young T; Sled JG; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2023 Sep; 95():104762. PubMed ID: 37586112
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir-induced neural tube defects in mice are folate responsive.
Tukeman GL; Wei H; Lin YL; Wlodarczyk BJ; Finnell RH; Cabrera RM
AIDS; 2024 Mar; 38(4):439-446. PubMed ID: 37382903
[TBL] [Abstract][Full Text] [Related]
5. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
6. Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Public Health; 2020 Dec; 20(1):1883. PubMed ID: 33287795
[TBL] [Abstract][Full Text] [Related]
7. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
9. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
10. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
11. Lessons from dolutegravir and neural tube defects.
Abrams E; Myer L
Lancet HIV; 2021 Jan; 8(1):e3-e4. PubMed ID: 33387476
[No Abstract] [Full Text] [Related]
12. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
Chandiwana NC; Chersich M; Venter WDF; Akpomiemie G; Hill A; Simmons B; Lockman S; Serenata CM; Fairlie L; Moorhouse MA
AIDS; 2021 Feb; 35(2):205-211. PubMed ID: 33086234
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
[TBL] [Abstract][Full Text] [Related]
14. Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.
Zamek-Gliszczynski MJ; Zhang X; Mudunuru J; Du Y; Chen JL; Taskar KS; Huang J; Huang Y; Romach EH
Drug Metab Dispos; 2019 Aug; 47(8):890-898. PubMed ID: 31167838
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
17. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
18. Interaction between dolutegravir and folate transporters and receptor in human and rodent placenta.
Gilmore JC; Hoque MT; Dai W; Mohan H; Dunk C; Serghides L; Bendayan R
EBioMedicine; 2022 Jan; 75():103771. PubMed ID: 34954655
[TBL] [Abstract][Full Text] [Related]
19. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
20. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
